泽璟制药(688266) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥92,492,835.06, representing a year-over-year increase of 64.67%[8] - The cumulative revenue for the year-to-date was ¥197,892,872.37, reflecting a 100.75% increase compared to the same period last year[8] - Total operating revenue for the first three quarters of 2022 reached ¥197,892,872.37, a significant increase from ¥98,578,591.59 in the same period of 2021, representing a growth of approximately 100.5%[35] - The company's operating revenue for the first three quarters of 2022 reached ¥236,412,440.22, a significant increase of 100.4% compared to ¥117,787,134.67 in the same period of 2021[59] - The net loss for the third quarter of 2022 was ¥387,326,926.68, compared to a net loss of ¥308,171,381.97 in the same quarter of 2021, showing an increase in losses of about 25.7%[38] - The net loss for the first three quarters of 2022 was ¥336,243,751.03, compared to a net loss of ¥274,524,146.75 in the same period of 2021, representing a decline of 22.4%[59] - The total comprehensive loss for the third quarter of 2022 was ¥381,175,502.95, compared to a loss of ¥309,139,327.19 in the previous year, indicating an increase of approximately 23.3%[40] Expenses and Costs - Research and development expenses totaled ¥137,107,979.55 in Q3 2022, accounting for 148.24% of revenue, a decrease of 100.24 percentage points compared to the same period last year[12] - Total operating costs for the first three quarters of 2022 were ¥617,167,804.62, up from ¥448,640,606.12 in 2021, indicating an increase of about 37.6%[35] - Research and development expenses amounted to ¥392,485,200.59 in the first three quarters of 2022, compared to ¥337,082,287.48 in 2021, reflecting a rise of approximately 16.4%[35] - The total operating costs for the first three quarters of 2022 were ¥48,844,500.60, up from ¥19,767,507.54 in the previous year, reflecting a growth of 146.5%[59] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,632,982,796.46, down 6.47% from the previous year[12] - As of September 30, 2022, the company's total assets amounted to approximately ¥1.63 billion, a decrease from ¥1.75 billion at the end of 2021, reflecting a decline of about 6.5%[27] - The company's current assets totaled approximately ¥1.26 billion, down from ¥1.41 billion, indicating a decrease of around 10.2%[29] - The total liabilities of the company reached approximately ¥756.77 million, up from ¥492.88 million, indicating an increase of around 53.5%[33] - The total liabilities of the company as of the reporting date were ¥666,171,618.99, up from ¥434,421,857.67 in the previous year, reflecting a growth of 53.2%[54] Cash Flow - The company’s cash flow from operating activities was -¥280,907,547.95 year-to-date[12] - Operating cash inflow for the first three quarters of 2022 was CNY 316,518,316.19, a significant increase from CNY 119,775,624.60 in the same period of 2021, representing a growth of approximately 164.5%[46] - The net cash outflow from operating activities was CNY -280,907,547.95, an improvement compared to CNY -328,639,988.58 in the previous year[46] - Cash inflows from operating activities totaled ¥298,445,033.10 in the first three quarters of 2022, compared to ¥119,616,215.39 in the same period of 2021, marking an increase of 149.9%[62] Equity and Shareholder Information - The net profit attributable to shareholders was -¥116,736,319.76 for the quarter, with a cumulative net profit of -¥363,745,077.96 year-to-date[8] - The company's total equity attributable to shareholders of the parent company decreased to ¥843,297,105.59 from ¥1,196,323,124.03 year-over-year, a decline of about 29.5%[35] - The total equity decreased to ¥901,657,213.27 from ¥1,210,671,197.63 year-over-year, a decline of 25.5%[54] Product Development and Market Position - The company has only one product on the market, which is still in the early commercialization stage, necessitating continued investment in marketing and academic promotion[18] - The company has not reported any significant new product developments or market expansions during the reporting period[25] - The company’s R&D investment remains high as multiple innovative drugs are in critical trial phases[18]